1
|
Hu L, Shi S, Song X, Ma F, Ji O, Qi B. Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC. Eur J Med Chem 2024; 265:116074. [PMID: 38142512 DOI: 10.1016/j.ejmech.2023.116074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 12/10/2023] [Accepted: 12/17/2023] [Indexed: 12/26/2023]
Abstract
Starting from the binding mode of allosteric EGFR inhibitor JBJ-04-125-02 and the key pharmacophore of the third-generation EGFR inhibitors, we designed and synthesized a novel series of EGFR inhibitors, represented by (R)-N-(4-((2-aminopyrimidin-4-yl)amino)phenyl)-2-(5-(4-(4-methylpiperazin-1-yl)phenyl)-1-oxoisoindolin-2-yl)-2-phenylacetamide (6q). Docking study demonstrated that top compound 6q spanned orthosteric and allosteric sites of EGFR, and formed three key H-bonds with the residues Asp855, Lys745, and Met793 located in two sites. Biological evaluation indicated that compound 6q showed potential inhibitory activity against Ba/F3-EGFRL858R/T790M/C797S and Ba/F3-EGFRDel19/T790M/C797S cells, with IC50 values of 0.42 μM and 0.41 μM, respectively. Furthermore, compound 6q showed excellent activity against mutant NSCLC cell line NCI-H1975-EGFRL858R/T790M/C797S cells, with IC50 value of 0.82 μM which was superior to that of osimertinib (IC50 = 2.94 μM), JBJ-04-125-02 (IC50 = 3.66 μM), and coadministration of JBJ-04-125-02 and osimertinib (IC50 = 1.25 μM). Cell cycle arrest and cell apoptosis assay indicated that compound 6q could promote apoptosis of NCI-H1975-EGFRL858R/T790M/C797S cells at the concentration of 0.8 μM and no obvious cell cycle arrest was found.
Collapse
Affiliation(s)
- Liping Hu
- School of Bioengineering, Zunyi Medical University, Zhuhai, 519041, China; Key Laboratory of Biocatalysis&Chiral Drug Synthesis of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China
| | - Shengmin Shi
- School of Bioengineering, Zunyi Medical University, Zhuhai, 519041, China; Key Laboratory of Biocatalysis&Chiral Drug Synthesis of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China
| | - Xiaomeng Song
- School of Bioengineering, Zunyi Medical University, Zhuhai, 519041, China; Key Laboratory of Biocatalysis&Chiral Drug Synthesis of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China
| | - Fangli Ma
- School of Bioengineering, Zunyi Medical University, Zhuhai, 519041, China; Key Laboratory of Biocatalysis&Chiral Drug Synthesis of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China
| | - Oulian Ji
- School of Bioengineering, Zunyi Medical University, Zhuhai, 519041, China; Key Laboratory of Biocatalysis&Chiral Drug Synthesis of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China
| | - Baohui Qi
- School of Bioengineering, Zunyi Medical University, Zhuhai, 519041, China; Key Laboratory of Biocatalysis&Chiral Drug Synthesis of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China.
| |
Collapse
|